How AI Can Help Alleviate the Stress of a Cancer Diagnosis
In an era where cancer rates continue to rise, the emotional toll a cancer diagnosis and the subsequent treatment journey has [...]
ASCO 2024: Randomized PROSTATE-IQ Trial to Reduce ADT Treatment Burden for Patients with Biochemical Recurrence After Prostatectomy
The 2024 American Society of Clinical Oncology (ASCO) Annual Meeting held in Chicago, IL between May 31st and June 4th, 2024 [...]
Artera Announces Three Presentations at ASCO 2024 That Demonstrate the Reliability and Depth of its AI Cancer Platform
Artera, the developer of multimodal artificial intelligence-based prognostic and predictive cancer tests, will present three [...]
New Data Validating the First AI-Based Biomarker to Stratify Risk of Metastasis in Radical Prostatectomy Patients with Biochemical Recurrence
Artera, the developer of multimodal artificial intelligence-based prognostic and predictive cancer tests, announced the valid [...]
Doctors Explain What Prostate Cancer Screenings Involve
If you've never had a prostate cancer screening, you may worry that it will be embarrassing and uncomfortable. Doctors say th [...]
ArteraAI and Movember Announce New Relationship
ArteraAI, the developer of multimodal artificial intelligence (MMAI) based predictive and prognostic cancer tests, today anno [...]
ArteraAI Prostate Test Included in NCCN Guidelines
The National Comprehensive Cancer Network (NCCN) Clinical Practice Guidelines for Prostate Cancer have included the ArteraAI [...]
ArteraAI Included in the 2024 NCCN Guidelines® for Prostate Cancer
ArteraAI, the developer of multimodal artificial intelligence (MMAI) based predictive and prognostic cancer tests, announced [...]
Here’s how AI will drive health care to meet consumer expectations
The rapid transformation of the health care landscape is undeniable. It is marked not only by groundbreaking technologies and [...]